US biotech firm Alexion Pharmaceuticals (Nasdaq: ALXN) has appointed Ludwig Hantson as chief executive and member of the board of directors, effective immediately.
Dr Hantson most recently served as president and CEO of Baxalta, a successful spin-off as a public company from Baxter, and a global leader in the development of therapies for orphan and underserved diseases in hematology, immunology and oncology, the acquisition of which by Ireland-headquartered Shire (LSE: SHP) was completed in June last year.
Dr Hantson brings to Alexion a strong record of developing diverse rare disease pipelines and commercializing innovative and life-transformative therapies at industry-leading companies, said Alexion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze